Eliza R Bacon

Dr. Eliza R Bacon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Neurobiology of Aging
Verified
Journal Article
Closed access
EBEliza R Bacon
Eliza R Bacon
AMAarti Mishra
Aarti Mishra
YWYiwei Wang
Yiwei Wang
MDMaunil K. Desai
Maunil K. Desai
FYFei Yin
Fei Yin
RBRoberta Diaz Brinton
Roberta Diaz Brinton

28 February 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
EBEliza R Bacon
Eliza R Bacon
RBRoberta Diaz Brinton
Roberta Diaz Brinton

28 November 2020 in Translational Medicine Communications
Verified
Journal Article
Open access
PDF file
EBEliza R Bacon
Eliza R Bacon
KIKena Ihle
Kena Ihle
PLPeter P. Lee
Peter P. Lee
JWJames R. Waisman
James R. Waisman
Background: Rapid Autopsy Programs offer an opportunity to collect tissue from patients immediately after death, providing critical biological material necessary to develop more effective therapies and improve patient outcomes. Here, we present a step-by-step guide to build a cancer-focused Rapid Autopsy Program, based on our own experiences building “The Legacy Project” at the City of Hope Comprehensive Cancer Center. Methods: The linear timeline of events is separated into four phases: 1) Building the Infrastructure, 2) Recruiting and Consenting, 3) Preparing for Death, and 4) Tissue Collection and Follow up. Important considerations and methods for adaptation are discussed throughout the protocol. Discussion: Using these methods, we successfully collected a total of 533 specimens from 9 subjects. The average time from death to last specimen acquisition was 6.1 h (range: 4.03–7.66 h; median: 5.71 h). A diverse team with various areas of expertise is critical for successful program implementation. Our goal herein this protocol is to provide a comprehensive framework and foundation for other institutions to use as a model.

29 March 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
EBEliza R Bacon
Eliza R Bacon
KIKena Ihle
Kena Ihle
WGWeihua Guo
Weihua Guo
CEColt A. Egelston
Colt A. Egelston
DSDiana L. Simons
Diana L. Simons
JWJames R. Waisman
James R. Waisman
The biology of metastatic breast cancer (MBC) is understudied, primarily due to the difficulty of procuring multiple samples from patients with oligometastatic breast cancer. We developed a rapid postmortem tissue procurement program that allows the collection and analysis of numerous metastatic lesions, subclinical locations, and potential pre-metastatic niches that fall within this scope. We conducted a rapid postmortem tissue collection study on 9 patients with MBC. Patients and their families consented to donate tissues immediately after death in an IRB-approved study. Various disease subtypes, progression histories, organ involvement, and final causes of death are reported. In patients with hormone receptor-positive (HR+) disease, estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 expression were heterogeneous across metastatic lesions within individual patients. Disease phenotype at the end of life trended toward complete loss of HR expression. Nearly all (n = 7) patients exhibited extensive tumor involvement of additional organs that had not been previously diagnosed clinically and were not retrospectively visible on recent imaging. Of these seven individuals, three included organs uncommonly associated with MBC: kidney, spleen, pancreas, and ovary. Finally, we identified clinically undetectable micrometastases in several organs uncommonly involved in MBC. Our findings raise several clinically relevant questions regarding the mechanisms of metastatic progression. Insights from this study argue for better surveillance strategies for monitoring MBC. We highlight the need to capture more accurate biomarker information in the context of heterogeneous disease and urge the consideration of treatment strategies that combine multiple targeted therapies.

24 July 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
CEColt Egelston
Colt Egelston
WGWeihua Guo
Weihua Guo
DSDiana L. Simons
Diana L. Simons
JYJian Ye
Jian Ye
CAChristian Avalos
Christian Avalos
PLPeter P. Lee
Peter P. Lee
Immune composition within the tumor microenvironment (TME) plays a central role in the propensity of cancer cells to metastasize and respond to therapy. Previous studies have suggested that the metastatic TME is immune-suppressed. However, limited accessibility to multiple metastatic sites within patients has made assessing the immune TME difficult in the context of multiorgan metastases. We utilized a rapid postmortem tissue collection protocol to assess the immune composition of numerous sites of breast cancer metastasis and paired tumor-free tissues. Metastases had comparable immune cell densities and compositions to paired tumor-free tissues of the same organ type. In contrast, immune cell densities in both metastatic and tumor-free tissues differed significantly between organ types, with lung immune infiltration being consistently greater than that in the liver. These immune profiling results were consistent between flow cytometry and multiplex immunofluorescence–based spatial analysis. Furthermore, we found that granulocytes were the predominant tumor-infiltrating immune cells in lung and liver metastases, and these granulocytes comprised most PD–L1–expressing cells in many tissue sites. We also identified distinct potential mechanisms of immunosuppression in lung and liver metastases, with the lung having increased expression of PD-L1+ antigen-presenting cells and the liver having higher numbers of activated regulatory T cells and HLA-DRlow monocytes. Together, these results demonstrate that the immune contexture of metastases is dictated by organ type and that immunotherapy strategies may benefit from unique tailoring to the tissue-specific features of the immune TME.

17 June 2026
Verified
Other
Open access
CEColt Egelston
Colt Egelston
WGWeihua Guo
Weihua Guo
DSDiana L. Simons
Diana L. Simons
JYJian Ye
Jian Ye
CAChristian Avalos
Christian Avalos
PLPeter P. Lee
Peter P. Lee
Immune cell densities across tissue sites. Mean densities of immune cell subsets as determined by flow cytometry are displayed across tumor-free and tumor-involved tissues. Means were calculated across all collected patient tissues with the number of included data points shown as ‘n’. Table values are colorized from least dense (blue) to most dense (red).